OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s lead candidate, OR2805, has entered clinical studies with a unique and transformative approach to the advancement of cancer therapeutics. OncoResponse is based in Houston, Texas and Seattle, Washington.
View Top Employees from OncoResponse| Website | http://oncoresponse.com |
| Revenue | $3 million |
| Funding | $79.1 million |
| Employees | 35 (35 on RocketReach) |
| Founded | 2016 |
| Address | 609 Main Street Suite 4200, Houston, Texas 77030, US |
| Phone | (206) 805-1600 |
| Fax | (206) 805-1699 |
| Technologies |
JavaScript,
HTML,
Google Analytics
+7 more
(view full list)
|
| Industry | Business Services, Research, Biopharma, Biotechnology, Health Care, Science and Engineering, Therapeutics |
| Competitors | Ambrx, Capralogics Inc, Cogent Biosciences, Surface Oncology Inc., Sutro Biopharma, Inc. |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 5419 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 54199 Companies |
Looking for a particular OncoResponse employee's phone or email?
OncoResponse Questions
The OncoResponse annual revenue was $3 million in 2024.
Clifford Stocks is the CEO of OncoResponse.
35 people are employed at OncoResponse.
OncoResponse is based in Houston, Texas.
The NAICS codes for OncoResponse are [5419, 54, 541, 54199].
The SIC codes for OncoResponse are [873, 87].
Top OncoResponse Employees
-
53
-
54
-
25
-
33
-
1
-
23
-
42
-
55+
Related Companies
